Invivoscribe
Business Services · California, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
10222 Barnes Canyon 1 Rd Bldg, San Diego...Phone Number
(858) 224-6600Website
www.invivoscribe.comRevenue
$85.7 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
1
1
2
1
1
About Invivoscribe
Invivoscribe develops precision molecular diagnostic assays, reagents, software, and clinical laboratory services that help physicians detect and monitor blood cancers, guide treatment decisions, and support personalized oncology care through companion diagnostics and biomarker testing.Explore more
Invivoscribe Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Invivoscribe your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Invivoscribe is spiking on competitors!
Invivoscribe, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Invivoscribe
Website visits: Recent activity has been detected on your website
Check if Invivoscribe has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Invivoscribe recently announced quarterly report
Click to see if Invivoscribe had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Invivoscribe has new funding data
Product Launch: Get notified when Invivoscribe launches new products
Recommended Actions
Find VP level buyers at Invivoscribe
Find more new buyers
Compare Similar Companies to Invivoscribe
Compare insights from companies similar to Invivoscribe, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Invivoscribe is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Invivoscribe is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Invivoscribe.
Invivoscribe financials insights
Gather financial insights about Invivoscribe, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Debt
$5M
Invivoscribe Tech Stack
A closer look at the technologies used by Invivoscribe
Most Recent Scoops
Hiring Plans
Invivoscribe has more open roles in Information Technology than it has had at any time in the past 12 months. Technologies mentioned include: Oracle Fusion, and Oracle Cloud Infrastructure.
Hiring Plans
Hiring Plans
Invivoscribe has more open roles in Information Technology than it has had at any time in the past 6 months. Technologies mentioned include: Oracle Fusion.
Hiring Plans
Open Position
Open Position
Invivoscribe News & Media
Invivoscribe’s LabPMM Gains New York State Approval for the FLT3 ITD MRD Assay
SAN DIEGO--(BUSINESS WIRE)--Invivoscribe is proud to announce that its wholly owned subsidiary, the Laboratory for Personalized Molecular Medicine® (LabPMM), LLC has received approval from the New York State Department of Health to offer the FLT3 ITD MRD Assay to assess measurable residual disease (MRD). LabPMM’s ultra-sensitive next generation sequencing FLT3 ITD MRD Assay provides clinicians with critical insights to tailor acute myeloid leukemia (AML) treatments and improve patient outcomes.EU Notified Body (BSI Netherlands) and the EMA Grant Approval of the LeukoStrat® CDx FLT3 Mutation Assay for VANFLYTA® Therapy in the EU and EEA
SAN DIEGO--(BUSINESS WIRE)-- #invivoscribe--Invivoscribe is excited to announce that their CE-2797 IVD certified LeukoStrat® CDx FLT3 Mutation Assay has been approved by BSI (Netherlands) and the EMA to aid in the selection of individuals in the European Union and European Economic Area with newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML) who may be eligible to receive treatment with Daiichi Sankyo’s VANFLYTA® (quizartinib). BSI, a Notified Body accredited in the EU, is authorizedStudy Suggests Critical Link Between Residual FLT3-ITD Mutations in Remission and Post-Transplant Outcomes in AML
SAN DIEGO--(BUSINESS WIRE)-- #AML--A groundbreaking research study,1 sequencing DNA samples from the Pre-MEASURE study2 strongly indicates that the detection of residual FLT3 internal tandem duplication (ITD) mutations in the blood of adult subjects with acute myeloid leukemia (AML) in first complete remission (CR) is associated with worse outcomes after post allogeneic hematopoietic cell transplant (HCT). This follow-up study performed measurable residual disease (MRD) testing on DNA of 537 subInvivoscribe Announces FDA Approval of the LeukoStrat CDx FLT3 Mutation Assay to Select Patients with FLT3-ITD Positive AML for Treatment with VANFLYTA
SAN DIEGO, July 21, 2023 /PRNewswire/ -- Invivoscribe is excited to announce that the LeukoStrat® CDx FLT3 Mutation Assay has been approved by the U.S. Food and Drug Administration (FDA) to aid in the selection of patients with newly diagnosed FLT3-ITD positive acute myeloid leukemia...
Read more news
Top Business Services Companies
See more top companies
Frequently Asked Questions Regarding Invivoscribe
Sign Up For FreeTo access detailed company insights
Invivoscribe develops precision molecular diagnostic assays, reagents, software, and clinical laboratory services that help physicians detect and monitor blood cancers, guide treatment decisions, and support personalized oncology care through companion diagnostics and biomarker testing.... Read More
